ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Geza Jak Reportedly Picked For Cancer Panel; Supreme Court To Hear Cigarette Label Case

April 12, 1991

NCI “Much Stronger” Now, Rimer Says In Note To Staff.

September 21, 2001

Childhood cancer Death Rates Decline, Incidence Stable, NCI Says In Report

July 30, 1999

Mammography For Women Under 50 Debated; Cut Of 3-4% Offered As Budget Trimmer

July 23, 1976

Millers Win Bristol-Myers $25,000 Award

May 19, 1978

NCI Gets Long List Of Consortium Center Needs, Including New Guidelines, Review, More “Glue”

September 14, 1984